The ANK3 Bipolar Disorder Gene Regulates Psychiatric-Related Behaviors That Are Modulated by Lithium and Stress

Melanie P. Leussis, Erin M. Berry-Scott, Mai Saito, Hueihan Jhuang, Georgius de Haan, Ozan Alkan, Catherine J. Luce, Jon M. Madison, Pamela Sklar, Thomas Serre, David E. Root, and Tracey L. Petryshen

Background: Ankyrin 3 (ANK3) has been strongly implicated as a risk gene for bipolar disorder (BD) by recent genome-wide association studies of patient populations. However, the genetic variants of ANK3 contributing to BD risk and their pathological function are unknown.

Methods: To gain insight into the potential disease relevance of ANK3, we examined the function of mouse Ank3 in the regulation of psychiatric-related behaviors using genetic, neurobiological, pharmacological, and gene-environment interaction (G×E) approaches. Ank3 expression was reduced in mouse brain either by viral-mediated RNA interference or through disruption of brain-specific Ank3 expression was associated with elevated stress reactivity.

Results: RNA interference of Ank3 in hippocampus dentate gyrus induced a highly specific and consistent phenotype marked by decreased anxiety-related behaviors and increased activity during the light phase, which were attenuated by chronic treatment with the mood stabilizer lithium. Similar behavioral alterations of reduced anxiety and increased motivation for reward were also exhibited by Ank3+/− heterozygous mice compared with wild-type Ank3+/+ mice. Remarkably, the behavioral traits of Ank3+/− mice transitioned to depression-related features after chronic stress, a trigger of mood episodes in BD. Ank3+/− mice also exhibited elevated serum corticosterone, suggesting that reduced Ank3 expression is associated with elevated stress reactivity.

Conclusions: This study defines a new role for Ank3 in the regulation of psychiatric-related behaviors and stress reactivity that lends support for its involvement in BD and establishes a general framework for determining the disease relevance of genes implicated by patient genome-wide association studies.

Key Words: Ankyrin G, dentate gyrus, GWAS, mouse, RNA interference, schizophrenia

Bipolar disorder (BD) is a severe psychiatric disorder for which the pathogenesis is poorly understood. BD is defined by alternating episodes of mania and depression, with manic symptoms including impulsivity, high-risk behavior, increased pleasure seeking (hedonia), and decreased sleep, whereas depressive symptoms include anhedonia, impaired cognition, and suicidality (1). Mood regulation in BD is unstable, and a manic or depressed episode can be triggered by many factors, including stress (2). Clinical studies highlight altered neurocircuit function in BD, notably increased limbic activity and decreased frontal cortical activation during emotional processing tasks (3).

It is well established that BD has a large genetic component (1). Patient genome-wide association studies (GWAS) have identified several genes associated with BD surpassing statistical correction for genome-wide testing (4). Of these, ANK3 was among the most significant in a recent meta-analysis of BD GWAS data from nearly 17,000 subjects, although the results did not replicate in all samples (5). As reviewed elsewhere (6), ANK3 also appears to be a shared risk factor between BD and schizophrenia based on a joint GWAS analysis (7) and has been implicated in anhedonia, stress signal processing, novelty seeking, and cognition in humans (8–10). ANK3 expression is lower in schizophrenia postmortem brain (10), suggesting that downregulation may underlie psychopathology. However, like many genes implicated in multifactorial disorders, ANK3 has a modest effect, with an odds ratio less than 1.35 for BD (5). The genetic variants associated with disease have no known function and may only be markers for the putative causal variant(s). It therefore remains unclear whether ANK3 is indeed a psychiatric risk gene and, if so, how it contributes to psychopathology.

ANK3 encodes many diverse isoforms of the ankyrin G scaffold protein functioning in various biological processes (11). The most recognized function of ankyrin G in the brain is formation and maintenance of the axon initial segment (AIS) of neurons. In this subcellular domain and at nodes of Ranvier, ankyrin G links voltage-gated sodium and potassium channels to the cytoskeleton (11) and is required for the production and propagation of...
action potentials mediated by these channels (12). Ankyrin G is also necessary for localization of inhibitory gamma-aminobutyric acid (GABA) synapses at excitatory neuron AIS (13), subventricular zone neurogenesis (14), and potentially synaptic transmission (15,16), among other functions.

Increasingly, GWAS are identifying genetic loci associated with psychiatric disorders, but determining the basis for these associations remains a formidable challenge. Although current disease knowledge may suggest a compelling hypothesis for the influence of a particular gene, such information is typically too sparse to support a specific mechanism. In this study, we explored a new role of ANK3 in neural circuits regulating mood using an integrative approach encompassing genetic, neurobiological, pharmacologic, and environmental components. We used two complementary genetic approaches to suppress the mouse Ank3 gene in brain, RNA interference targeting specific circuits and whole brain transgenic knockout, that provide highly consistent and persuasive evidence for a novel function of Ank3 in modulating psychiatric-related behaviors and stress reactivity. Our study provides compelling support for the human genetic data implicating ANK3 in psychiatric disease. More broadly, this work establishes a general framework for validating newly implicated psychiatric GWAS risk genes and examining their putative disease-relevant functions.

Methods and Materials

Detailed methods can be found in Supplement 1.

Animals

Male 8-week-old C57BL/6J mice were used for RNA interference studies. Male 8- to 11-week old Ank3+/- and Ank3+/+ knockout mice (12) were generated from male Ank3+/- and female C57BL/6J crosses.

Lentiviral-Mediated RNA Interference

To minimize the possibility of off-target effects, two short hairpin RNA sequences (shRNA1 or shRNA2 targeting Ank3 exons 19 or 28) that suppress mRNA expression in vitro by 75% to 80% (Figure S1A in Supplement 1) were compared with a control shRNA (shCON) that does not target any known mouse transcripts.

Corpus hippocampum dentate gyrus was injected bilaterally with lentivirus expressing shRNA1, shRNA2, or shCON (n = 10–11 mice/group).

Behavior

Mice were evaluated using conventional, well-validated assays for measuring behaviors mediated by neural circuits implicated in psychiatric illness, as well as sensory and motor performance (17,18). These included locomotor activity in a novel open field, elevated plus maze (EPM), light-dark transition (LD), novelty-suppressed feeding (NSF), acoustic startle, prepulse inhibition, home cage activity, sucrose preference, forced swim test (FST), contextual and cued fear conditioning, and visual performance in a visible platform water maze.

Drug Treatment

Lithium chloride (85 mg/kg intraperitoneal; Sigma-Aldrich, St. Louis, Missouri) or vehicle (saline with 0.2% acetic acid) was administered once daily for 14 days before and throughout behavioral testing 1 hour before testing.

Immunohistochemistry

Coronal sections from 4% paraformaldehyde fixed brains were incubated with appropriate antibodies and processed using standard methods.

Corticosterone Measurements

Plasma corticosterone levels following acute restraint stress were measured using an enzyme immunoassay (EIA).

Statistical Analysis

All data are presented as means and standard errors of the mean (SEM). Where appropriate, one-way, two-way, and repeated-measures analysis of variance were used, and group differences identified using Fisher’s least significant difference post hoc tests. Statistical significance was accepted at the p < .05 level.

Results

Ank3 RNA Interference in Dentate Gyrus Produces a Highly Specific Phenotype Marked by Lower Anxiety-Related Behavior

Ank3 expression was reduced by viral-mediated RNA interference in hippocampal dentate gyrus (DG), given its role in BD, mood and stress regulation, and mood stabilizer response (19–23). Across nine behavioral assays, Ank3 suppression in the DG with either of two shRNA sequences targeting Ank3, shRNA1 or shRNA2, produced a highly specific and sizable reduction in anxiety-related behavior in the EPM. Mice expressing shRNA1 or shRNA2 exhibited 60% to 75% shorter latencies (i.e., less time) to enter the EPM open arms, 50% more open arm entries, and threefold more time in the open arms, compared with mice injected with a control sequence, shCON (Figure S3 in Supplement 1). These changes were not due to hyperactivity because the number of total arm entries or rears in the EPM (Figure S3 in Supplement 1) and open field activity (Figure S4 in Supplement 1) did not differ from shCON. Ank3 knockdown mice did not differ from controls in conventional tasks assessing sensorimotor gating (prepulse inhibition), auditory and visual sensory performance (acoustic startle response and visible platform Morris water maze), associative learning (cued and contextual fear conditioning), or the FST (Figure S4 in Supplement 1). Overall, these data suggest that Ank3 suppression in DG results in a specific reduction in anxiety-related behavior.

Following behavioral assessment and confirmation of correct virus placement, we measured knockdown of ankyrin G expression in DG granule cells infected with shRNA lentivirus by identifying cells expressing green fluorescent protein from the virus. We specifically examined neuronal AIS because ankyrin G is highly expressed and plays a critical role at this subcellular location. Ankyrin G AIS expression was significantly decreased by 45% and 62% in shRNA1 and shRNA2 mice, respectively, relative to shCON mice (n = 5/group; F(2,8) = 8.8, p < .01; Figure 1). These results suggest that partial reduction of ankyrin G expression in DG granule cells is sufficient to cause marked behavioral changes.

Behavioral Changes Associated with Ank3 Knockdown Are Reversed by Lithium Treatment

We performed an independent experiment to evaluate the effects of lithium in reversing the behavioral alterations induced by Ank3 RNA interference. Given the consistent behavioral effects noted, we examined only shRNA2 because it targets more Ank3 isoforms than shRNA1. Fourteen days after lentivirus injection into bilateral DG, mice were treated with lithium at a clinically
relevant dose (85 mg/kg intraperitoneal; see Supplement 1) or with vehicle for 14 days before and throughout behavioral testing (n = 8–12 mice/group). Lithium effects were assessed by comparing shRNA2 mice treated with lithium to shCON mice treated with vehicle that index the normal condition.

Replicating the previous result, Ank3 RNA interference in DG substantially decreased anxiety-related behavior. Specifically, vehicle-treated shRNA2 mice exhibited 60% shorter latency and 40% increased frequency to enter the EPM open arms [F(1,17) = 5.54, p = .03; F(1,17) = 4.61, p = .046; Figure 2A,B] compared with vehicle-treated shCON mice. Notably, lithium treatment normalized the behavior, in that lithium-treated shRNA2 mice did not significantly differ from vehicle-treated shCON mice in EPM open arm latency or entries (p > .1 Figure 2A,B). These results were confirmed using the LD task, where there was a significant interaction between shRNA and lithium treatment in the latency to leave the dark and enter the light side [F(1,33) = 4.78, p = .036; Figure 2C]. Vehicle-treated shRNA2 mice exhibited 65% shorter latency to enter the light side compared with vehicle-treated shCON mice (post hoc p = .02), and lithium treatment increased this latency such that shRNA2 mice did not differ from vehicle-treated shCON mice (post hoc p > .1). We also tested NSF, which assesses the latency to approach and eat food in the center of a novel arena that mice innately avoid. There was a significant shRNA by drug interaction [F(1,31) = 5.44, p = .026; Figure 2D] in the NSF approach latency. Vehicle-treated shRNA2 mice exhibited 80% shorter latency to approach than vehicle-treated shCON mice (post hoc p = .005), whereas lithium treatment normalized the latency of shRNA2 mice such that there was no significant difference from vehicle-treated shCON mice (post hoc p = .29). As in the behavioral screen described earlier, mice expressing shRNA2 did not differ from shCON mice in motor activity in the open field, EPM, or LD tasks (Figure S5 in Supplement 1). Thus, across three paradigms, Ank3 suppression in DG was associated with substantially decreased anxiety-related behaviors that were normalized by lithium treatment.

Because BD patients report sleep disruptions during both manic and depressive episodes (24), we assessed changes in motor activity across the light–dark cycle using an automated home-cage behavioral phenotyping system (25). Mice expressing shRNA2 showed no significant differences compared with shCON mice in the total time engaged in activity (walking, hanging, rearing, grooming, eating, drinking) during the dark phase [F(1,33) = 1.9, p > .1; Figure 2F] when mice, being nocturnal, are most active. However, during the light phase, shRNA2 mice were 53% more active than shCON mice [F(1,33) = 4.61, p = .039; Figure 2E]. Lithium treatment reversed the increased light phase activity of shRNA2 mice to levels similar to vehicle-treated shCON mice (post hoc p = .6; Figure 2E). These results indicate that in addition to decreased anxiety-related behaviors, Ank3 suppression in DG is associated with elevated activity during the light phase of the light–dark cycle, which is normalized by lithium treatment.

Reduction of Ank3 Brain-Specific Isoforms Induces Behavioral Changes Consistent with Dentate Gyrus Knockdown

To gather further support and extend our behavioral findings from Ank3 RNA interference mice, we performed a

---

**Figure 1.** Ank3 RNA interference markedly decreases ankyrin G expression at neuronal axon initial segments (AIS). (A) In mouse brain, dentate gyrus cells infected with lentivirus expressing shRNA (green, green fluorescent protein (GFP)-positive infected cells; red, ankyrin G). White box demarcates the region where ankyrin G expression was measured. (B) Representative images of neurons infected with lentiviral vectors expressing shCON, shRNA1, or shRNA2 targeting mouse Ank3. Ankyrin G (red) was measured at the AIS (demarcated by a white line) of neurons containing GFP (green) expressed from the lentiviral vector. (C) Quantification of ankyrin G expression showing decreases of 45% and 62% by shRNA1 and shRNA2, respectively, compared with shCON. Mean ± SEM; n = 5 mice/group, 6 AIS/mouse; *p < .05. GCL, granule cell layer; H, hilus; ML, molecular layer; shCON, control shRNA; shRNA, short hairpin RNA.
Ank3+/– mice were examined (n = 7–18/group). Compared with wild-type Ank3+/+ mice, heterozygous Ank3+/– mice are reported to have reduced forebrain and cerebellar expression of the 270- and 480-kD ankyrin G isoforms that localize to the AIS (12,26). We verified that Ank3+/– mice have a significant 39% reduction in ankyrin G expression at neuronal AIS in the DG granule cell layer compared with Ank3+/+ littermates [t(6 df) = 4.6, p < .01; Figure 4A], similar to the RNA interference mice (Figure 1). Furthermore, ankyrin G expression at the AIS of cortical neurons was decreased by 41% in Ank3+/– mice compared with Ank3+/+ mice [t(8 df) = 6.2, p < .001; Figure 4B]. Together with the published data, these results suggest that Ank3+/– mice with a single functional copy of brain-specific isoforms have reduced ankyrin G expression at neuronal AIS throughout the brain.

We found that male Ank3+/– mice exhibited behavioral alterations that were highly consistent with the decreased anxiety-related phenotype of RNA interference mice (Table S3 in Supplement 1) and also displayed other relevant behaviors. Compared to Ank3+/+ littermates, Ank3+/– mice exhibited substantially shorter latencies to enter the EPM open arms (57% reduced, post hoc p < .05, Figure 5A) and LD light side (59% reduced, post hoc p = .07, Figure 5B), and to approach food in the NSF task (83% reduced, post hoc p < .05, Figure 5C). To consider other attributes relevant to mood, we measured preference to drink a 1% sucrose solution over water. Ank3+/– mice exhibited 53% greater sucrose preference compared to Ank3+/+ littermates (post hoc p < .05, Figure 5D), suggesting heightened motivation to obtain a reward. As with Ank3 RNA interference mice, Ank3+/– mice were normal in all other behavioral tests including open field activity, acoustic startle, prepulse inhibition, contextual and cued fear conditioning, and motor activity in the EPM and LD tasks (Figure 5E; Tables S1 and S3 in Supplement 1). The highly consistent behavioral changes in Ank3+/– mice further demonstrate a previously unknown function of Ank3 brain-specific isoforms in regulating psychiatric-related behaviors.

### Chronic Stress Induces a Shift to Depressive-like Features in Ank3+/– Mice

Because stress is a major risk factor for BD episode recurrence (2) and the hypothalamic-pituitary-adrenal (HPA) axis is implicated in BD (27), we examined the effect of chronic stress on Ank3+/– mice.

**Figure 2.** Ank3 RNA interference in dentate gyrus (DG) is associated with lower anxiety-related behavior and increased light-phase activity that is normalized by lithium treatment. Vehicle-treated mice expressing shRNA2 against Ank3 in the DG, when compared with shCON mice, exhibit (A) shorter latency to enter the open arms and (B) greater number of open-arm entries in the elevated plus maze, (C) shorter latency to enter the light–dark transition light side, (D) shorter latency to approach food in the novelty-suppressed feeding task, and (E) increased activity during the light phase but (F) no change in activity during the dark phase. (A–E) Lithium treatment (85 mg/kg intraperitoneal, >14 days) normalizes the behavioral alterations of shRNA2 mice to similar levels as vehicle-treated shCON mice. (F) Lithium has no impact on dark-phase activity in either shCON or shRNA2 mice. Mean ± SEM; n = 8–12 mice/group; *p < .05, **p < .01. shCON, control shRNA; shRNA, short hairpin RNA.

**Figure 3.** Ank3 exon 1b transcripts are expressed in multiple brain regions. Normalized expression of Ank3 transcripts containing the brain-specific exon 1b or widely expressed exon 1e across brain regions, as measured by Nanostring gene expression analysis. For each brain region, mRNA from eight C57BL/6J mice was pooled before measurement. Exon 1b transcripts are more highly expressed than exon 1e transcripts across all brain regions examined. DG, dentate gyrus; dHipp, dorsal hippocampus; mPFC, medial prefrontal cortex; OFC, orbitofrontal cortex; vHipp, ventral hippocampus.
Compared with Ank3+/+ littermates, Ank3+/- mice singly housed for 6 weeks did not exhibit increased motivation for reward or decreased anxiety-related behaviors (Figure 5 isolated condition), as found under standard group-housed conditions described above (Figure 5, group condition). Specifically, isolated Ank3+/- mice did not display significantly shorter latencies to enter the EMP open arms or LD light side or to approach food in the NSF task when compared with either group-housed or isolated Ank3+/+ mice (all post hoc t values > .09, Figure 5A-C). There was also a change in motivation (Figure 5D): isolated Ank3+/- mice did not display significantly increased sucrose preference compared with isolated Ank3+/+ mice (p > .05), as was observed under group-housed conditions, and had substantially lower sucrose preference, relative to group-housed Ank3+/- mice (post hoc p < .05). Chronic isolation also resulted in 50% greater FST immobility in Ank3+/- mice versus Ank3+/+ mice (p < .05, Figure 5E), whereas group-housed Ank3+/+ and Ank3+/- mice did not differ (p > .05, Figure 5E). The latter results are suggestive of a depression-related phenotype in Ank3+/- mice exposed to stress, because the increase in FST immobility is opposite to the reduced immobility induced by antidepressant treatment (28). Thus, chronic stress induced a transition in Ank3+/- mice from decreased anxiety-related behaviors and increased motivation to depression-related features, highlighting an environmental component in mood regulation. Interestingly, the isolation stress had no effect on Ank3+/+ mice (all p values > .09; Figure 5, group vs. isolation housed), suggesting a putative gene-environment (GxE) interaction in which diminished Ank3 is associated with elevated stress sensitivity.

**Evidence for Altered Stress Hormone Reactivity in Ank3+/- Mice**

To investigate the mechanism through which chronic stress modifies the phenotype of Ank3+/- mice, we measured plasma levels of corticosterone, the predominant stress hormone in rodents, and weight of the adrenal gland that produces corticosterone, as a measure of chronic stress load (29). Under group housing, the ratio of adrenal weight to body weight ratio did not differ between Ank3+/+ and Ank3+/- mice, nor did isolation have any effect on the adrenal:body weight ratio of wild-type Ank3+/- mice (all post hoc p values > .1; Figure 6A). In contrast, isolated Ank3+/- mice exhibited a 27% increase in adrenal:body weight ratio compared to group-housed Ank3+/- mice (p < .01; Figure 6A), suggesting that Ank3+/- mice are more reactive to chronic stress than wild-type mice. Ank3+/- mice exhibited higher basal corticosterone levels than Ank3+/+ littermates, regardless of group or isolation housing [F(1,10) = 9.03 and F(1,11) = 9.04, both p values < .05; Figure 6C,D; Table S2 in

---

**Figure 4.** Ank3+/- mice have substantially reduced ankyrin G expression at the axon initial segments (AIS) of dentate gyrus and cortical neurons. Compared with Ank3+/+ littermates, heterozygous Ank3+/- mice exhibit an approximately 40% reduction in ankyrin G at the AIS of neurons in the (A) dentate gyrus and (B) cortex, as measured by immunohistochemistry. Mean ± SEM; n = 5–7 mice/group, 6–7 AIS/mouse; **p < .01.

**Figure 5.** Ank3+/- mice exhibit distinctive behavioral alterations that are modified by chronic stress. Under standard group-housed conditions compared with Ank3+/+ littermates, Ank3+/- mice display shorter latencies (A) to enter the elevated plus maze (EMP) open arms, (B) to enter the light–dark (LD) transition light side, and (C) to approach food in the novelty-suppressed feeding (NSF) task; (D) they also exhibit greater preference for sucrose over water. In contrast, after prolonged isolation housing, Ank3+/- mice no longer exhibit shorter latencies to enter (A) the EMP open arms or (B) the LD light side, (C) or to approach food in the NSF task, (D) nor do they display greater sucrose preference, compared with isolation-housed Ank3+/+ mice. (E) Group-housed Ank3+/- mice do not differ from Ank3+/+ mice in FST immobility time, whereas isolation housing significantly increased Ank3+/- immobility time. Mean ± SEM; n = 7–18 mice/genotype; **p < .01, *p < .05, **p < .01, unpaired t test.

www.sobp.org/journal
exhibit a higher corticosterone peak 30 min after acute restraint stress as mice/genotype; **

Isolation-housed mice exhibit a phenotype remarkably similar to Ank3+/– mice, with reduced neural expression of the glucocorticoid receptor and exaggerated by acute stress, suggesting impaired HPA axis integrity in Ank3+/– mice. The elevated stress reactivity of Ank3+/– mice compared to Ank3+/+ mice suggests a G×E interaction in which the level of Ank3 expression modulates the impact of stress on brain function. One putative mechanism through which Ank3 may mediate stress reactivity is through dysregulated HPA axis activity, as suggested by elevated corticosterone levels and adrenal gland weight following chronic isolation stress in Ank3+/– mice compared with Ank3+/+ mice. Notably, mice with reduced neural expression of the glucocorticoid receptor exhibit a phenotype remarkably similar to Ank3+/– mice, including decreased anxiety-related behavior, impaired behavioral response to stress, and altered HPA axis regulation (32), supporting a link between HPA axis function and the behavioral changes observed in Ank3+/– mice. Future experiments to examine HPA axis integrity in Ank3+/– mice, as well as ankyrin G function following chronic stress, will be important to elucidate the role of ankyrin G in stress reactivity.

Our data suggest that Ank3 may influence a broader repertoire of emotional behaviors beyond those associated mainly with BD. Further insight into its nuanced role could be obtained through human genetic association studies of other psychiatric disorders and psychological traits, as well as by evaluating defined behaviors and related neural circuitry in mice with perturbed Ank3 expression (18). For example, tasks that specifically assess impulsivity and risk-taking may clarify the observed decrease in anxiety-related behaviors (30,31). This is an important distinction given that low anxiety is not typically associated with BD, whereas impulsive and risk-taking behaviors are key characteristics. It will also be important to assess sleep and circadian rhythm, which are implicated in BD (24), to follow-up our finding of increased light phase activity in Ank3 RNA interference mice.

There are several potential reasons why the ANK3 genetic variants identified by human GWAS have small effects, whereas robust changes in mood states are observed in Ank3+/– mice. It is possible that the human variants produce a more subtle change in ankyrin G function than that caused by the approximately 40% reduced expression in Ank3+/– mice. Alternatively, the human ANK3 genetic changes may have larger effects in some individuals than others because of variation in genetic background or other factors, but the effect is diluted across heterogeneous human populations. In contrast, robust effects may be more easily revealed in precisely controlled experiments using genetically homogeneous mouse lines.

Although our data provide compelling evidence that Ank3 functions in neural processes regulating psychiatric-related behaviors, more research is clearly required to determine whether Ank3 suppression in mice is a valid model of BD. We are aware of only two other genetic manipulations in mice that induce features of both decreased anxiety and increased depression. These are knockout of the D-box binding protein gene (Dbp) and RNA suppression of Clock, which, interestingly, reduces anxiety-related behaviors similar to that observed in this study (33,34).
A contrasting phenotype of increased anxiety (decreased exploration) and antidepressant-like behavior is found in mice haploinsufficient for another BD GWAS-implicated gene, the voltage-gated calcium channel alpha subunit Cacna1c (35). A similar mood-stabilized phenotype also occurs in mice haploinsufficient for the lithium target glycogen synthase kinase 3 beta (GSK-3β) or overexpressing its substrate β-catenin (36–38), which is notable given the reversal of behavioral changes by lithium in this study and that GSK-3β and β-catenin have been implicated in ankyrin G tethering at the AIS (39).

The overwhelming consistency between both Ank3 mouse models has several implications. First, it indicates that the Ank3 shRNA sequences were "on target" because two distinct shRNAs are unlikely to produce the same off-target effects. Second, the role of Ank3 in behavioral regulation is likely attributable to one or more brain-specific transcripts that are disrupted in Ank3+/− mice and suppressed by both shRNA sequences. However, pinpointing the specific transcript(s) is impeded by the large number of Ank3 splice variants (>10 reported to date) that necessitates in-depth molecular studies, for example, reversal studies using viral-mediated gene transfer of individual complementary DNA (cDNA) sequences into brain. The unwieldy cDNA size of the 270- and 480-kD ankyrin G isoforms located at the AIS, however, precludes packaging into conventional viruses with persistent in vivo expression. Lastly, we can speculate that the DG is critical for the observed phenotypes because it was targeted by our RNA interference and Ank3 exon 1b transcripts disrupted in Ank3+/− mice are expressed in this region. The DG is indeed implicated in exploration (40) and untrained anxiety-related responses such as those elicited in the EPM, LD, and NSF tasks (41). Altered DG function may also perturb hippocampal and downstream circuits that could directly regulate behavior, such as the septohippocampal circuit that mediates inhibition of behavioral responses (42,43).

There are several mechanisms through which lithium may exert the observed behavioral effects. Known targets include GSK-3, AKT kinase, the phosphoinositol pathway, and the extra-cellular regulated kinase/mitogen activated protein kinase cascade (44). Alternatively, other known properties of lithium may involve, such as increasing hippocampal volume (21), DG synaptic plasticity and granule cell firing (23), or adult DG neurogenesis (22). Interestingly, Ank3 loss in the subventricular zone disrupts the production of adult newborn neurons in mice (14). Ank3 may have a similar role in the DG, such that Ank3 downregulation could impair adult neurogenesis, leading to behavioral alterations that are restored by lithium.

Our study provides a framework for addressing the daunting challenge in medical genetics research of elucidating the functional relevance of genes implicated by patient GWAS. We used two complementary genetic approaches to manipulate gene expression, assessed several biological processes related to the disease, established pharmacologic validity using a clinical medication, and demonstrated a G×E interaction with an environmental trigger of disease symptoms. Furthermore, our study followed recent recommendations for animal studies of candidate psychiatric risk genes (18) because it evaluated changes in behavior using a wide range of paradigms and focused on chronic manipulations of environment (e.g., stress). Applying a similar integrative approach to other risk genes may also provide insight into their possible pathological functions.

Overall, this study provides compelling evidence that reduced Ank3 expression is associated with altered psychiatric-related behaviors and stress reactivity. Our discovery of a previously unknown role of Ank3 in behavioral regulation highlights avenues for future investigation of the potential functional relevance of ANK3 to psychopathology.

**Funding** was provided by the Stanley Medical Research Institute (to JM, PS, TLP), The RNAi Consortium (to DER), the Massachusetts General Hospital Executive Committee on Research (to MPL), the McGovern Institute Neurotechnology Program (to TS), and the Robert J. and Nancy D. Carney Fund for Scientific Innovation (to TS).

We thank Thomas Nieland (RNA interference), Doug Barker, Erroll Rueckert, Jennifer Moran, Nicholas Sanchez, and Kimberly Chambert (Nanostring gene expression), Ben Samuels and Elizabeth Clare (behavior assay development), and Keenan Richards, Misha Riley, and Katherine Isley (laboratory assistance) for their assistance. We also thank Vann Bennett, Roy Perlis, Janice Kranz, and Steven Hyman for helpful comments on previous versions of this article.

Dr. Serre reports receiving research funding from Bristol Myers Squibb. Dr. Sklar reports having received a consultant fee from Pfizer and reports a patent on brain-derived neurotrophic factor and bipolar disorder. The other authors report no biomedical financial interests or potential conflicts of interest.

**Supplementary material** cited in this article is available online.


www.sobp.org/journal


The Ups and Downs of Bipolar Disorder Research

Richard S. Jope and Charles B. Nemeroff

Bipolar disorder is a debilitating disease that continues to thwart a tremendous effort to understand its pathogenesis. Consequently, new treatment development has also languished. However, some inroads have been achieved. The first of these was undoubtedly the discovery that lithium stabilizes mood in a significant portion of patients with bipolar disorder. Not only was lithium pivotal for the treatment of this severe psychiatric disorder, but it also provided a critical tool to examine responses in patients and laboratory animals to acquire clues about the etiology of bipolar disorder (Figure 1), as indeed it was used in two reports published in this issue of Biological Psychiatry (1,2). These reports each examined responses to lithium in applications of two newer advances applied to bipolar disorder, imaging technologies capable of examining human brains in vivo (3), and molecular methods that have identified genetic variations in subpopulations of patients with bipolar disorder (4). These reports exemplify the power by which bipolar disorder research can take advantage of the remarkable mood-stabilizing action of lithium in combination with newly developed technologies. However, just as the disease is characterized by unpredictable fluctuations in mood, so too are advances in understanding its etiology vulnerable to alternating cycles of apparent clarity and ambiguity.

Advances in structural and functional imaging of the human brain have provided unique insights in a multitude of neurologic and psychiatric disorders. Among these is bipolar disorder, in which imaging methods have helped to pinpoint affected brain regions and changes that occur in response to therapeutic interventions. One of the most intriguing and reproducible insights about bipolar disorder obtained from structural magnetic resonance imaging (MRI) studies are the reports (1) that lithium treatment increased brain gray area volumes in bipolar patients. This suggested that lithium may reverse degeneration or structural alterations of neurons that accompany the disease. That interpretation fit exceedingly well with evidence from preclinical studies that lithium increases adult neurogenesis (5), increases the production of neurotrophins, such as brain-derived neurotrophic factor, and reduces neuronal damage and death in response to a variety of insults (6), all mechanisms that could conceivably increase gray matter. However, the report by Cousins et al. (1) in this issue of Biological Psychiatry appears to have dashed the hopes that an important therapeutic action of lithium had been identified. They tested the hypothesis that lithium may directly alter the MRI signals, a possibility noted but not followed-up by some previous investigators, which could lead to the spurious conclusion that lithium increased gray matter volume. MRI signal intensities used for volumetric analysis are commonly derived from the T1 relaxation properties of water. The presence of lithium shortens the T1 relaxation properties of water, which alters the MRI signal, tissue contrast, and volumetric analysis. Cousins et al. (1) showed that this direct effect of lithium on MRI signals can lead to the erroneous conclusion that lithium treatment increases gray matter volume, in part by showing that lithium did not alter gray matter volume when calculated using methods independent of T1 relaxation properties. This clarification answers the riddle of why MRI measurements indicated that gray matter volumes were increased by lithium administered to healthy controls who presumably did not suffer from abnormal neuronal degeneration or reduced neurogenesis, although, as the authors noted, the reported lithium-induced changes were generally greater in bipolar patients than control subjects. Will this finding end attempts to identify responses to lithium using MRI techniques? This is highly unlikely, and hopefully the opposite will occur, as the authors challenge other investigators to reexamine their data and to take into account lithium’s direct effects on MRI signals in future studies. Such rigorous reassessments can be expected to lead to revisions in our understanding of how lithium affects the brain and to reveal new leads for future investigations. This report is an important reminder that defining the limitations of new technologies is as valuable as findings of significant changes. In the long term, this report should enhance the power of imaging techniques to clarify responses to lithium and other therapeutic agents.

Examining the effects of lithium administration also played an important role in the study by Leussis et al. (2) in this issue of Biological Psychiatry. They followed up the finding from genome-wide association studies (GWAS) that ankyrin 3 (ANK3) is a risk gene for bipolar disorder by studying ANK3-deficient mice. A broad range of analyses revealed alterations in only certain behaviors, particularly those commonly attributed to anxiety assessments, i.e., the elevated plus maze and light-dark transition measurements. In these behaviors, ANK3 deficiency reduced anxiety-like behaviors, which could be interpreted as being related to the mania-linked characteristic of increased risk taking, and these diminished anxiety-like responses of ANK3-deficient mice were normalized by lithium treatment. After being singly housed for 6 weeks, ANK3-deficient mice displayed the intriguing trait of responding to the isolation stress in a somewhat opposite manner to wild-type mice in anxiety-related behaviors, and isolation-stressed ANK3-deficient mice also displayed diminished preference for sucrose and increased despair, or depression-like behavior, in the forced swim test. Thus, the authors noted that chronic isolation stress induced a transition in ANK3-deficient mice “from decreased anxiety-related behaviors and increased motivation to depression-related features” (2) and suggested this was due to altered corticosterone regulation in ANK3-deficient mice. Still to be determined are the effects of lithium on the behavioral responses to stress in the ANK3-deficient mice. These findings reveal a novel gene-environment interaction between ANK3 and stress. This is a valuable confirmation that GWAS, often criticized for failure in studies of psychiatric diseases, are providing meaningful clues about factors involved in bipolar disorder that can be studied in rodents, although the difficulties in interpreting rodent behaviors in terms of mood disorders continues to be an important limitation, as discussed previously (7). However, most importantly, this study can be considered another step in the validation of the utility of GWAS in identifying

From the Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida.

Address correspondence to Richard S. Jope, Ph.D., Miller School of Medicine, University of Miami, 1011 NW 15th St, Gautier Building, Room 416, Miami, Florida 33136; E-mail: rjope@med.miami.edu.

Received Dec 22, 2012; accepted Dec 27, 2012.

http://dx.doi.org/10.1016/j.biopsych.2012.12.014

© 2013 Society of Biological Psychiatry
risk genes for bipolar disorder and demonstrates the important role played by lithium in supporting links to bipolar disorder in behavioral measurements in rodents.

Both of these reports (1,2) demonstrate the important role that advanced technologies play in biomedical research in general and bipolar disorder more specifically but also reveal the difficulties in interpreting results, and they highlight the continuing seminal position that lithium has in bipolar disorder research (Figure 1). Imaging and genetic advances provide the means to delve into aspects of bipolar disorder not possible a decade ago. But limitations in the manner in which the data are interpreted and related to bipolar disorder continue to obstruct advances. Computer-generated analyses that are required for handling the large databases obtained in imaging and genetic studies can generate many novel findings but also make difficult critical analyses of individual findings. The MRI findings of lithium-induced increased gray matter volumes fit so well with preclinical studies of lithium’s effects that this may have helped to obscure technical problems that perhaps should have been evaluated more closely initially. Risk genes identified in GWAS can generate new hypotheses about bipolar disorder etiology, but testing these in rodents that may not be capable of displaying manic and depressive behaviors requires a stretch of interpretation of genetic links to bipolar disorder. However, we can still rely on lithium, the remarkable ion that remains the gold standard of treatment for patients with bipolar disorder and serves an invaluable role in bipolar disorder research. It is difficult to imagine examining bipolar disorder-linked phenotypes in rodent models without including tests of lithium’s effects. Furthermore, identified responses to lithium finally can often be linked to mechanisms. A decade ago lithium appeared to have a multitude of targets, but these have been narrowed down because a great many of the actions of lithium now can be attributed to its inhibition of glycogen synthase kinase-3 (GSK3) (7). GSK3 is currently known to phosphorylate nearly 100 substrates (8), so its inhibition by lithium can account for many of the diverse actions of lithium that have been reported, including the activation of Akt and the extracellularly regulated kinase cascade, increased neurogenesis, and altered synaptic plasticity (9,10) mentioned by Leussis et al. (2). Thus, clarification of the mechanism of action of lithium goes hand in hand with deciphering the causes of bipolar disorder, and lithium may prove to be as valuable in stabilizing fluctuations in bipolar disorder research as it is in stabilizing mood in bipolar disorder.

Research in the authors’ laboratories was supported by grants from the National Institute of Mental Health (MH038752 and MH094759).

RSJI reports no biomedical financial interests or potential conflicts of interest. CBN has received research support from the National Institutes of Health and the Agency for Healthcare Research and Quality. He has served as a consultant to Xhale, Takeda, and SKPharma. He has been a stockholder in CeNeRx Biopharma, NovaDel Pharma Inc, PharmaNeuroboost, RevaaX Pharma, and Xhale. He has also had additional financial interests in Corcept, CeNeRx BioPharma, PharmaNeuroboost, Novadel Pharma, and RevaaX. He has served on the scientific advisory boards of American Foundation for Suicide Prevention, AstraZeneca, CeNeRx Biopharma, Forest Labs, Janssen/Ortho-McNeil, Mt Cook Pharma Inc, NARSAD, NovaDel Pharma, Inc, Pharma-Neuroboost, Quintiles, and the Anxiety Disorders Association of America. He has also served on the Board of Directors for the American Foundation for Suicide Prevention, George West Mental Health Foundation, NovaDel Pharma, Inc., and Mt. Cook Pharma Inc. He holds a patent on the method and devices for transdermal delivery of lithium (US 6,375,990 B1) and the method to estimate drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).


